

ICC International Cannabis Corp.

15:15 30 May 2019

ICC International Cannabis, Biotii and Y Combinator-backed biotech innovator to build Bioworks Foundry

ICC International Cannabis Corp (CSE: WRLD.U) (OTC: WLDCF) announced Thursday that along with Biotii Technologies Corp it has sealed a design and automation agreement with Y Combinator-backed Opentrons Labworks Inc to collaboratively build Canada's first privately owned high-throughput Bioworks Foundry.

International Cannabis already has a strategic investment in Boston, Massachusetts-based Biotii, a top private biotechnology company.

The new Bioworks Foundry will function as a staging ground for Biotii's cannabinoid researchers and organism designers to manufacture and analyze prototype enzyme pathways, said the company in a statement.

READ: ICC International Cannabis is growing a worldwide cannabis cultivation and lifestyle brand

The planned facility will give International Cannabis and Biotii the opportunity to scale synthesized cannabinoid testing processes rapidly and cost-effectively by using:

- Advanced DNA assembly protocols
- Laboratory automation
- High performance analytics

The completion of the Bioworks Foundry will catapult Biotii into an elite clutch of less than 20 labs worldwide that are equipped with the ability to automate genome assembly of multiple DNA fragments.

Opentrons robots for biologists

Opentrons, which makes robots for biologists, will supply the foundry with its flagship OT-2 Robot to give Biotii access to a proven molecular biology platform, furnished with hundreds of existing protocols and over 5,400 software commits from a diverse community of researchers, including teams from Stanford University and the Mayo Clinic.

With International Cannabis' financial backing and Opentrons' advanced engineering frameworks going into the planned Bioworks Foundry, the Biotii team hopes to deliver on its 2020 mandate to produce cannabinoid in hundreds of metric tonnes per annum boasting:

- Stable and consistent yields
- Pharmaceutical-grade purities
- Lowest production costs in the space

The company said Biotii's scalable synthesizing processes will enable the manufacture of "a wide range of cannabinoids," including tetrahydrocannabinol (THC) and cannabidiol (CBD) inexpensively compared to conventional cultivation and extraction processes.

Making revolutionary products

Price: US\$0.065

Market Cap: US\$43423100M

Share Information

Code: WRLD.U

Listing: CSE

52 week	High	Low
	\$0.54	\$0.06

Sector: Cannabis [T3]

Website: intlcanibiscorp.com

Company Synopsis:

ICC International Cannabis' corporate mandate is to plan, design, build and operate the highest quality, lowest cost Cannabis production, processing and distribution facilities worldwide. ICC boasts an in-depth understanding of both the cannabis and biomedical industries, as well as world-class experience within the many associated cannabis industry vehicles and derivatives.

action@proactiveinvestors.com

"Within the sphere of biological engineering living organisms are the foundational factories by which revolutionary products are devised," said ICC International Cannabis CEO David Shpilt. "Designing preeminent synthetic cannabinoids requires a different category of factory, one where best-in-class tools in automation, analytics, and software can all function in symbiotic fashion."

Shpilt said the automated Bioworks Foundry will permit "efficient scaling of organism design," thereby allowing engineers to expedite the prototyping of thousands of unique biological designs.

"Opentrons presents a flexible platform and supports a growing community of users, providing ICC and Biotii with access to continuously expanding set of modules, protocol, and capabilities," said Shpilt.

Opentrons OT-2 Robot enables the execution of complex, repetitive task-loads that cannot be replicated by traditional human lab staff.

"The OT-2, for example, can run four times as many experiments in the same sized plate, and efficiently dispense liquids with precision in much less time," said Shpilt.

Accelerating cannabinoid R&D

The Bioworks Foundry will accelerate cannabinoid R&D, allowing the companies to capture significant IP within the fast-developing biosynthesis market for cannabinoids.

"With Opentrons, we are ready to start building our revolutionary Bioworks Foundry. We have the flexibility to develop whatever automated processes we want, even, and especially, if the manufacturer hasn't thought of it yet," said Biotii's co-founder and CEO Dr John Harrold. "This will give Biotii and ICC the advantage in developing not only our target products faster, but also the tools to produce subsequent targets more efficiently."

Meanwhile, Will Canine, co-founder and CPO of Opentrons, a company that's setting out to help life scientists automate many of their experiments using robotics, said he was happy to start a "relationship with Biotii and ICC."

"I am excited to see what new uses Biotii's engineers will be come up with to get the most out of the OT-2," said Canine.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.